BioMarin Pharmaceutical Inc. announced the acquisition of Amicus Therapeutics for $4.8 billion in an all-cash transaction.
The acquisition will enhance BioMarin's presence in the rare diseases market and accelerate revenue growth.
This strategic move is expected to strengthen BioMarin's financial outlook and add significant value to patients, employees, and stockholders.
Acquisition Deal
BioMarin to acquire Amicus Therapeutics for $4.8 billion, expanding its position in rare diseases.
Revenue Growth
The acquisition is expected to accelerate BioMarin's revenue growth and be accretive to Non-GAAP Diluted EPS.
Product Portfolio Expansion
The acquisition will diversify BioMarin's rare disease product portfolio with two new treatments targeting lysosomal storage disorders.
- The acquisition will immediately expand and diversify BioMarin's commercial portfolio.
- It will provide opportunities to enhance access to existing treatments in new markets globally.
- The transaction is projected to create substantial shareholder value and accelerate revenue growth for BioMarin.
With the acquisition of Amicus Therapeutics, BioMarin strengthens its position in the rare diseases market, expands its product portfolio, and accelerates revenue growth. This strategic move is expected to benefit patients, employees, and stockholders in the long term.